TABLE 3.

Characteristics of patients with treatment failure^a

Age	Clinical indication	Pathogen	Dosing	Comment
30	BSI with abscess	MRSA	1,500 mg ×1b	Recurrence of purulent cellulitis with abscess due to intramuscular heroin injections into wound
34	OM, ABSSTI	MSSA	1,500 mg weekly ×2c	Assault victim that self-discharged 3 times without indicated surgical source control
52	ABSSTI, BSI, OM	MRSA	1,500 mg ×1b	Multiple self-discharges during which the patient declined the removal of the retained needle and incision and drainage
55	ABSSTI with BSI	MRSA	1,500 mg ×1b	Burn victim with acute on chronic worsening of wounds, unclear if recurrence or new infection
50	BSI	CoNSd	1,500 mg ×1b	Readmitted with concern for septic arthritis of the ankle

^aBSI, bloodstream indications; MRSA, methicillin-resistant Staphylococcus aureus; OM, osteomyelitis; ABSSTI, acute bacterial skin and soft tissue infections; MSSA, methicillin-sensitive Staphylococcus aureus, AMA, against medical advice; CoNS, coagulase negative Staphylococcus aureus.

^bReceived initial treatment course with IV vancomycin prior to dalbavancin.

^cReceived cefazolin prior to dalbavancin.

^d4 species of CoNS.